Table 5.
The statistically significant differences of the clinical characteristics and the laboratory findings between the fatality and the survival group for every patient and for only the patients who developed hepatitis
| Clinical characteristics | All patients
|
Patients with hepatitis
|
||||
|---|---|---|---|---|---|---|
| Patients who survived (40) | Patients who died (15) | p value | Patients who survived (23) | Patients who died (14) | p value | |
| AKI (%) | 11/39 (28.2%) | 14/15 (93.3%) | <0.001 | 10/23 (43.5%) | 13/14 (92.9%) | 0.003 |
| Jaundice (%) | 9/34 (26.5%) | 12/13 (92.3%) | <0.001 | 7/22 (31.8%) | 12/13 (92.3%) | 0.001 |
| Coagulopathy (%) | 6/23 (26.1%) | 13/13 (100%) | <0.001 | 5/14 (35.7%) | 13/13 (100%) | 0.001 |
| Initial AST results (IU/L), median (min–max) | 42.5 (18–5,500) | 2,350 (44–12,592) | <0.001 | 61 (21–5,500) | 3,137 (289–12,592) | <0.001 |
| Initial ALT results (IU/L), median (min–max) | 44.5 (12–6,268) | 1,787 (23–18,871) | <0.001 | 68 (13–6,268) | 2,100 (200–18,871) | <0.001 |
| Max AST results (IU/L), median (min–max) | 323 (18–12,300) | 5,750 (2,641–12,592) | <0.001 | 532 (135–12,300) | 5,750 (2,641–12,592) | <0.001 |
| Max ALT results (IU/L), median (min–max) | 451 (12–9,899) | 3,436.5 (1,684–18,871) | <0.001 | 607 (76–9,899) | 3436.5 (1,684–18,871) | <0.001 |
| Max total bilirubin results (mg/dL), median (min–max) | 1.2 (0.19–17.9) | 6.56 (0.5–28.3) | 0.011 | 1.34 (0.23–17.9) | 6.56 (0.5–28.3) | 0.004 |
| Max direct bilirubin results (mg/dL), median (min–max) | 0.4 (0.1–12.75) | 3.2 (0.2–18.49) | <0.001 | 0.5 (0.1–12.75) | 3.2 (0.2–18.49) | 0.001 |
| Max creatinine results (mg/dL), median (min–max) | 0.9 (0.33–3.9) | 3.5 (0.4–7.8) | <0.001 | 0.9 (0.33–3.9) | 3.5 (0.4–7.8) | <0.001 |
Abbreviations: AST, aspartate aminotransferase; ALT, alanine transaminase; AKI, acute kidney disord ; min, minimum; max, maximum.